Otsuka to take over Astellas’ Cefixime business

pharmafile | June 7, 2019 | News story | Medical Communications |  APIs, Antibiotics, Astellas, Otsuka, antimicrobial, pharma 

Japanese firm Otsuka Chemical has bought Astellas Pharma’s antibiotic Cefixime.

The agreement gives Otsuka the right to sell Cefixime and supply the active pharmaceutical ingredient (API) to overseas licensees.

The move comes as part of an effort from Otsuka to strengthen their grounding in the API business.

Astellas’ Cefixime is a third generation cephalosporin with antibacterial activity against gram-positive and gram-negative bacteria. The antibiotic is prescribed around the world.

Otsuka said they intend to further strengthen their business through new technologies as they take advantage of key technologies.

Louis Goss